Carbamoyl phosphate synthetase I deficiency disease
MONDO:0009376Carbamoyl-phosphate synthetase 1 deficiency (CPS1D) is a rare and severe disorder of urea cycle metabolism most commonly characterized by either a neonatal-onset of severe hyperammonemia that occurs few days after birth and manifests with lethargy, vomiting, hypothermia, seizures, coma and death or a presentation outside the newborn period at any age with (sometimes) milder symptoms of hyperammonemia.
Also known as: CPS1 deficiency, CPS1D, carbamoyl phosphate synthetase I deficiency disease, carbamoyl phosphate synthetase deficiency, carbamoyl-phosphate synthase deficiency disease, carbamoyl-phosphate synthetase I deficiency, carbamoyl-phosphate synthetase deficiency, carbamoylphosphate synthetase I deficiency
6 clinical trials for this condition and its sub-types, 4 tagged with Carbamoyl phosphate synthetase I deficiency disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
One-Time gene fix could free kids from lifelong diet and meds
Disease control Recruiting nowThis early-phase trial tests a single intravenous dose of a gene editing therapy called LNP.UCD.ABE in 7 children with severe urea cycle disorders. The therapy aims to correct the genetic defect using a lipid nanoparticle to deliver a base editor. The main goal is to check safety…
Phase 1/2 • Sponsor: Rebecca Ahrens-Nicklas • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for kids with rare metabolic disease: 5-Year trial launches
Disease control Recruiting nowThis study is testing a drug called glycerol phenylbutyrate in 40 Chinese children with urea cycle disorders, a rare genetic condition that causes dangerous ammonia buildup. The drug aims to help control ammonia levels over 5 years. Researchers will monitor safety and effectivene…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC